The Centers for Medicare and Medicaid Services (CMS) finalized a policy Thursday that broadens Medicare coverage for transcatheter aortic valve replacement (TAVR) to asymptomatic patients with severe aortic stenosis. Previously, coverage had been restricted to symptomatic individuals—those experiencing breathlessness, chest discomfort, or other signs of valve failure.
This change follows a broader trend in medical standards. In April 2025, the FDA expanded approval for Edwards Lifesciences’ Sapien 3 TAVR system to include asymptomatic patients with severe aortic stenosis. The agency’s decision was based on findings from the company’s EARLY TAVR study, which demonstrated that early intervention improved outcomes compared to watchful waiting—a strategy of monitoring without immediate treatment.
The CMS retained most of its June proposal but made one critical adjustment: symptomatic patients no longer require coverage with evidence development (CED), which had demanded data collection during treatment. Asymptomatic patients, however, remain subject to CED requirements, reflecting ongoing uncertainty among some medical groups about the long-term benefits for this population.
Industry analysts project the policy will gradually increase procedure volumes, though immediate effects may be modest. Edwards Lifesciences, which generates roughly 75% of its revenue from TAVR, welcomed the decision, calling it a positive step for patient access. The company maintained its 2026 financial outlook and plans to share updated projections at an investor meeting in December.
Medtronic, a competitor in the heart valve market, also supported the change, though TAVR accounts for only about 5.5% of its total revenue. Financial experts from firms like Stifel and BTIG viewed the CMS ruling as favorable for the sector, particularly for Edwards, which leads the TAVR market. They acknowledged that adoption could take time as medical professionals and hospitals adapt to the new criteria.
The CMS also announced plans to evaluate TAVR coverage for patients with aortic regurgitation, a condition where the valve fails to close properly, allowing blood to flow backward. A decision is expected by March 2027, following the FDA’s March 2025 clearance of JenaValve’s Trilogy system, the first TAVR device approved for this condition.
Some cardiologists and medical associations had advocated for stricter evidence requirements across all patient groups, citing incomplete long-term data on asymptomatic TAVR outcomes. The CMS’ decision to apply CED only to asymptomatic patients reflects a cautious approach, balancing expanded access with continued data collection. Whether this compromise will address concerns or speed up adoption remains uncertain.
The policy is effective immediately, though hospitals may face delays in identifying asymptomatic patients and verifying eligibility. Edwards has positioned the change as reinforcing its market leadership, but the ultimate test will be whether doctors, insurers, and patients consider TAVR a practical solution for those without symptoms. The first hurdle—removing the coverage barrier, has been cleared.
